Document is current
Any future updates will be listed below
-
Authors
Ogrinc, Katarina http://orcid.org/0000-0002-8134-749X
Bogovič, Petra
Maraspin, Vera
Lotrič Furlan, Stanka
Rojko, Tereza
Ružić-Sabljić, Eva
Kastrin, Andrej
Strle, Klemen
Wormser, Gary P.
Strle, Franc
-
Funding
Funding for this research was provided by:
University Medical Centre Ljubljana, Slovenia (20220127)
US National Institute of Allergy and Infectious Diseases (R21AI144916)
US National Institute of Arthritis and Musculosceletal and Skin Diseases (K01AR062098)
Slovenian Research and Innovation Agency (P3-0296, J3-1744, J3-8195)
- License Information
-
More Information
Article History
Received: 7 May 2024
Accepted: 28 June 2024
First Online: 9 July 2024
Declarations
:
: This research study was conducted retrospectively from data obtained for clinical purposes, was approved by the Medical Ethics Committee of the Ministry of Health of the Republic of Slovenia (0120–552/2023/3) and did not require written informed consent.
: K.S. served as a consultant for T2 Biosystems, Roche, BioMerieux, and NYS Biodefense Fund, for the development of diagnostic assays in Lyme borreliosis. G.P.W. reports receiving research grants from Biopeptides, Corp. and Pfizer, Inc. He is an unpaid board member of the non-profit American Lyme Disease Foundation. F.S. served on the scientific advisory board for Roche on Lyme disease serological diagnostics and on the scientific advisory board for Pfizer on Lyme disease vaccine and is an unpaid member of the steering committee of the ESCMID Study Group on Lyme Borreliosis/ESGBOR. Other authors have no relevant financial or non-financial interests to disclose.
